Table 2.
Summary of fold change IMF treatment differences in gene expression in the ARC, LH, and LC between male and female 12-month-old and 18-month-old mice. .
| Region | Gene | 12-month-old | 18-month-old | ||
|---|---|---|---|---|---|
| Male | Female | Male | Female | ||
| ARC | Agrp | ↑ | n.s. | n.s. | n.s. |
| Npy | ↑ | n.s. | ↑ | n.s. | |
| Hcrtrl | n.s. | n.s. | n.s. | n.s. | |
| Adrla | ↓ | n.s. | ↓ | n.s. | |
| Adrlb | n.s. | n.s. | n.s. | n.s. | |
| Kcnq3 | n.s. | n.s. | n.s. | n.s. | |
| Kcnq5 | n.s. | n.s. | n.s. | n.s. | |
| Pomc | n.s. | n.s. | n.s. | n.s. | |
| Cart | n.s. | n.s. | n.s. | ↓ trend | |
| LH | Hcrt | n.s. | n.s. | n.s. | ↓ |
| Npylr | ↓ | ↓ | n.s. | n.s. | |
| Npy5r | ↓ | n.s. | n.s. | n.s. | |
| Adrla | ↓ | n.s. | n.s. | n.s. | |
| Adrlb | ↓ | n.s. | n.s. | n.s. | |
| LC | Slc6a2 | n.s. | n.s. | n.s. | n.s. |
| Dbh | n.s. | n.s. | n.s. | n.s. | |
| Hcrtrl | n.s. | n.s. | n.s. | n.s. | |
Adr1a, alpha-1A adrenergic receptor; Adr1b, alpha-1B adrenergic receptor; Agrp, agouti-related protein; ARC, arcuate nucleus; Cart, cocaine- and amphetamine-regulated transcript; Dbh, dopamine β-hydroxylase; Hcrt, hypocretin neuropeptide precursor; Hcrtr1, hypocretin receptor 1; Kcnq2, potassium voltage-gated channel subfamily Q member 2; Kcnq3, potassium voltage-gated channel subfamily Q member 3; Kcnq5, potassium voltage-gated channel subfamily Q member 5; LC, locus coeruleus; Npy, neuropeptide Y; Npy1r, neuropeptide Y receptor 1; Npy2r, neuropeptide Y receptor 2; Pomc, proopiomelanocortin; Slc6a2, solute carrier family 6 member 2. ↑ = increased fold change in gene expression IMF-treated mice in contrast to controls; ↓ = decreased fold change in gene expression in IMF-treated mice in contrast to controls; n.s. = not significant.